Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Long-term safety of recombinant human growth hormone in children.

Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B.

J Clin Endocrinol Metab. 2010 Jan;95(1):167-77. doi: 10.1210/jc.2009-0178. Epub 2009 Nov 11.

PMID:
19906787
2.

Long-term safety of recombinant human growth hormone in turner syndrome.

Bolar K, Hoffman AR, Maneatis T, Lippe B.

J Clin Endocrinol Metab. 2008 Feb;93(2):344-51. Epub 2007 Nov 13.

PMID:
18000090
3.

Safety of growth hormone treatment of children with idiopathic short stature: the US experience.

Allen DB.

Horm Res Paediatr. 2011;76 Suppl 3:45-7. doi: 10.1159/000330159. Epub 2011 Sep 7.

PMID:
21912165
4.

Lessons from the national cooperative growth study.

Wyatt D.

Eur J Endocrinol. 2004 Aug;151 Suppl 1:S55-9.

5.

Effect of long-term recombinant growth hormone therapy in children--the National Cooperative Growth Study, USA, 1985-1994.

Root AW, Kemp SF, Rundle AC, Dana K, Attie KM.

J Pediatr Endocrinol Metab. 1998;11(3):403-12.

PMID:
11517956
6.

Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study.

Carel JC, Ecosse E, Landier F, Meguellati-Hakkas D, Kaguelidou F, Rey G, Coste J.

J Clin Endocrinol Metab. 2012 Feb;97(2):416-25. doi: 10.1210/jc.2011-1995. Epub 2012 Jan 11.

PMID:
22238382
7.

Use of growth hormone in children.

Hindmarsh PC, Dattani MT.

Nat Clin Pract Endocrinol Metab. 2006 May;2(5):260-8. Review.

PMID:
16932297
8.

Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study.

Sävendahl L, Maes M, Albertsson-Wikland K, Borgström B, Carel JC, Henrard S, Speybroeck N, Thomas M, Zandwijken G, Hokken-Koelega A.

J Clin Endocrinol Metab. 2012 Feb;97(2):E213-7. doi: 10.1210/jc.2011-2882. Epub 2012 Jan 11.

PMID:
22238393
9.

[Use of growth hormone in children and adolescents].

Bergadá I.

Medicina (B Aires). 2013;73(3):272-6. Spanish.

10.

Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy.

Claessen KM, Appelman-Dijkstra NM, Adoptie DM, Roelfsema F, Smit JW, Biermasz NR, Pereira AM.

J Clin Endocrinol Metab. 2013 Jan;98(1):352-61. doi: 10.1210/jc.2012-2940. Epub 2012 Nov 15.

PMID:
23162104
11.

Current indications for growth hormone therapy for children and adolescents.

Richmond E, Rogol AD.

Endocr Dev. 2010;18:92-108. doi: 10.1159/000316130. Epub 2010 Jun 3. Review.

PMID:
20523020
12.

Safety of recombinant human growth hormone.

Carel JC, Butler G.

Endocr Dev. 2010;18:40-54. doi: 10.1159/000316126. Epub 2010 Jun 3. Review.

PMID:
20523016
13.

Hormone replacement therapy in children: The use of growth hormone and IGF-I.

Pfäffle R.

Best Pract Res Clin Endocrinol Metab. 2015 Jun;29(3):339-52. doi: 10.1016/j.beem.2015.04.009. Epub 2015 Apr 29. Review.

PMID:
26051295
14.

GH therapy and cancer risk in hypopituitarism: what we know from human studies.

Pekic S, Popovic V.

Eur J Endocrinol. 2013 Oct 1;169(5):R89-97. doi: 10.1530/EJE-13-0389. Print 2013 Nov. Review.

15.

Adverse events with rhGH treatment of patients with chronic renal insufficiency and end-stage renal disease.

Fine RN, Ho M, Tejani A, Blethen S.

J Pediatr. 2003 May;142(5):539-45.

PMID:
12756387
16.

Growth hormone replacement therapy in children with leukemia in remission.

Taha DR, Bastian W, Castells S.

Clin Pediatr (Phila). 2001 Aug;40(8):441-5. Review.

PMID:
11516051
17.

Efficacy and safety of a new ready-to-use recombinant human growth hormone solution.

Romer T, Peter F, Saenger P, Starzyk J, Koehler B, Korman E, Walczak M, Wasik R, Ginalska-Malinowska M, Solyom E, Berghout A.

J Endocrinol Invest. 2007 Jul-Aug;30(7):578-89.

PMID:
17848841
18.

Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation.

Takeda A, Cooper K, Bird A, Baxter L, Frampton GK, Gospodarevskaya E, Welch K, Bryant J.

Health Technol Assess. 2010 Sep;14(42):1-209, iii-iv. doi: 10.3310/hta14420. Review.

19.

Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients.

Hartman ML, Xu R, Crowe BJ, Robison LL, Erfurth EM, Kleinberg DL, Zimmermann AG, Woodmansee WW, Cutler GB Jr, Chipman JJ, Melmed S; International HypoCCS Advisory Board.

J Clin Endocrinol Metab. 2013 Mar;98(3):980-8. doi: 10.1210/jc.2012-2684. Epub 2013 Jan 23.

20.

[Left ventricular mass and function in growth hormone deficient children and adolescents before and after one year of recombinant human growth hormone (GH) replacement therapy].

Szczepańska Kostro J, Tołwińska J, Urban M, Głowińska B.

Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2004;10(2):75-80. Polish.

PMID:
15504309
Items per page

Supplemental Content

Write to the Help Desk